A next-gen weight loss drug is raising the bar for type 2 diabetes treatment. Results from the phase 3 TRIUMPH-2 trial, presented at the European Association for the Study of Diabetes annual meeting and published in The Lancet, show that once-weekly retatrutide (Eli Lilly) delivered up to 18.8% body weight loss at 80 weeks in adults with type 2 diabetes and obesity — surpassing what's been seen with semaglutide and tirzepatide in comparable studies.

Retatrutide works by activating three hormone receptors — GLP-1, GIP, and glucagon — which together suppress appetite and regulate metabolism more aggressively than single or dual agonists. Adults with a BMI ≥35 kg/m² saw even greater results, with the 12 mg dose driving up to 21.9% weight loss. Beyond the scale, the drug also meaningfully improved HbA1c, blood pressure, triglycerides, and inflammatory markers.

By the Numbers:

• 18.8% average body weight loss with retatrutide 12 mg vs. 5.1% with placebo
• 21.9% weight loss in adults with BMI ≥35 kg/m² on the 12 mg dose
• 75% of patients on 12 mg achieved ≥10% weight loss vs. 21% on placebo
• HbA1c dropped by ~1.45 percentage points with the 12 mg dose vs. 0.45 with placebo
• Triglycerides fell 35.6% with 12 mg vs. 1.8% with placebo

Why it matters: With obesity and type 2 diabetes affecting hundreds of millions globally, a drug that tackles both conditions more effectively than current options could be a significant advance in metabolic care. Lilly has eight potential indications in its retatrutide pipeline — including cardiovascular, renal, and liver disease outcomes — signaling this could become one of the most versatile metabolic drugs in development.